

Regd. & Corp. Office:
1506, Chiranjiv Tower,
43, Nehru Place,
New Delhi - 110019 (INDIA)

Tel.: 011 - 47589500-51 (50 Lines),
E-mail: info@medicamen.com
Web: www.medicamen.com
CIN No.:
L74899DL1993PLC056594
Date: 28.06.2021

Ref: STEX/Results/Published-2021-22

The BSE Ltd
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400001

Company Number: 531146

**Sub. : Copy of Publication for Audited Financial Results for the quarter and year ended
March 31, 2021**

Dear Sir,

Pursuant to regulation 30 & 47 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015 ("the Regulations"), please find enclosed herewith the Audited Financial Results of the Company for the quarter and year ended on March 31, 2021 approved by the Board of Directors at their Meeting held on 26.06.2021.

The copy of the results published in the Financial Express and Jansatta dated June 27, 2021 is enclosed.


This is for your information and records.

Kindly acknowledge the receipt.

Thanking You,

Yours truly,
For Medicamen Biotech Limited

For Medicamen Biotech Limited


Parul Choudhary
Company Secretary
ACS-44157

Encl: As above.

For All Advertisements Book
Call : 0120-6651214

1) Total Income	(421.66)	2,002.72	(1,120.49)	(492.11)	2,489.00	(1,120.74)
2) Net profit / (Loss) for the period before Tax #	(491.61)	2,490.40	(1,120.49)	(492.11)	2,489.00	(1,120.74)
3) Net profit / (Loss) for the period after Tax #	93.90	2,133.59	(609.34)	95.63	2,132.19	(607.35)
4) Total Comprehensive income for the period (Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)	7,184.19	12,037.47	(6,752.41)	7,511.91	12,362.06	(6,854.75)
5) Equity Share Capital (Face value of Rs 10/- each)	100.09	100.09	100.09	100.09	100.09	100.09
6) Reserves (excluding Revaluation Reserves as per Balance sheet of previous year)		27,492.72			27,816.38	
7) Earning per Share (of Rs 10/- each)						
(a) Basic (not annualised)	9.38	213.16	(60.88)	9.49	213.07	(60.68)
(b) Diluted (not annualised)	9.38	213.16	(60.88)	9.49	213.07	(60.68)

#The Company does not have Exceptional / Extraordinary items to report for the above periods.

Notes:

- The above audited financial results for the quarter and year ended March 31 2021 have been reviewed by the Audit committee and on its recommendation have been approved by the Board of directors at its meeting held on June 26, 2021.
- The above is an extract of the detailed format of Financial Results for the quarter and year ended March 31, 2021 filed with the Stock Exchanges under the Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulation, 2015, as amended. The full format of the said 'Financial Results' are available on the website of Stock Exchange "www.bseindia.com." and on Company's website "www.saraswaticommercial.com."

For and on behalf of the Board of Directors
sd/-

Ritesh Zaveri
Director
DIN : 00054741

Date : June 26, 2021
Place : Mumbai

Sl. No.		Standalone		Consolidated					
		Quarter Ended		Year Ended		Quarter Ended		Year Ended	
Particulars		Audited 31.03.2021	Audited 31.03.2020	Audited 31.03.2021	Audited 31.03.2020	Audited 31.03.2021	Audited 31.03.2020	Audited 31.03.2021	Audited 31.03.2020
1	Total income from operations (net)	2087.47	1642.97	11090.06	11925.09	2177.60	2462.14	11347.01	12744.26
2	Net Profit/(Loss) for the period (before tax, exceptional and/or Extraordinary items)	464.35	200.86	1675.12	1660.39	410.07	338.49	1639.40	1798.02
3	Net Profit/(Loss) for the period before tax (after exceptional and/or Extraordinary items)	464.35	200.86	1675.12	1660.39	410.07	338.49	1639.40	1798.02
4	Net Profit/ (Loss) for the period after tax (after exceptional and/or Extraordinary items)	414.34	146.11	1248.66	1225.89	364.69	249.33	1212.94	1329.12
5	Total comprehensive income for the period (Comprising Profit/ (loss) for the period (after tax) and other Comprehensive income (after tax))	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
6	Equity Share Capital	1221.66	1221.66	1221.66	1221.66	1221.66	1221.66	1221.66	1221.66
7	Reserves (excluding Revaluation Reserve as shown in the Balance Sheet of previous year)								
8	Earnings Per Share (of Rs.10/- each) (for continuing and discontinued operation)								
	Basic:	3.39	1.20	10.22	10.09	2.99	2.05	9.93	10.94
	Diluted:	3.39	1.20	10.22	10.09	2.99	2.05	9.93	10.94

Note:

- The above results after being reviewed by the Audit Committee have been taken on record by the Board at its Meeting held on 26th June 2021.
- This statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- The company operates only in one business segment, viz. Pharmaceuticals formulations, hence segment reporting is not applicable
- The Earning Per Share has been calculated as per Indian Accounting Standard (Ind AS) 33 - "Earning per Share"
- During the quarter under review, major of the manufacturing facilities was shut down for 5-6 weeks for upgradation of plant as per regulatory market requirement for future growth.
- Audit report has been carried out by the Statutory Auditors for the above period.
- The figures are regrouped in previous year also, wherever considered necessary, to make them comparable.

Place: New Delhi
Date: 26.06.2021

For Medicamen Biotech Limited
Sd/-
Rahul Bishnoi
Chairman

प्रस्तावित शेयरों के निवेश

(अर्थात 30%) प्रति शेयर का अंतिम लाभांश संस्तुत किया जो आगामी एजीएम में शेयरधारकों के अनुमोदन के अधीन होगा।

3. उपर्युक्त सेबी (एलओडीआर), विनियम 2015 के विनियम 33 के तहत स्टॉक एक्सचेंजों के साथ दर्ज समाप्त तिमाही तथा वर्ष के लेखापरीक्षित परिणामों के विस्तृत प्रारूप का सारांश है। लेखापरीक्षित वित्तीय परिणामों का पूर्ण प्रारूप कम्पनी की वेबसाइट www.mohindra.asia तथा मेट्रोपोलिटन स्टॉक एक्सचेंज ऑफ इण्डिया लिमिटेड की वेबसाइट www.msei.com पर उपलब्ध है।

बोर्ड के लिए तथा उनकी ओर से

ह./-

दीपक अरनेजा (प्रबन्ध निदेशक तथा सीईओ)

डीआईएन : 00006112

तिथि : 26.06.2021

स्थान : नई दिल्ली



MEDICAMEN BIOTECH LTD.

Regd. Office: 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019

CIN : L74899DL 1993PLC056594 E-mail : cs@medicamen.com, www.medicamen.com

Extracts of Audited Standalone and Consolidated Financial Results for the Quarter and Year ended on 31.03.2021 (In Lakhs)

Sl. No.	Particulars	Standalone				Consolidated			
		Quarter Ended		Year Ended		Quarter Ended		Year Ended	
		Audited 31.03.2021	Audited 31.03.2020	Audited 31.03.2021	Audited 31.03.2020	Audited 31.03.2021	Audited 31.03.2020	Audited 31.03.2021	Audited 31.03.2020
1	Total income from operations (net)	2087.47	1642.97	11090.06	11925.09	2177.60	2462.14	11347.01	12744.26
2	Net Profit/(Loss) for the period (before tax, exceptional and/or Extraordinary items)	464.35	200.86	1675.12	1660.39	410.07	338.49	1639.40	1798.02
3	Net Profit/(Loss) for the period before tax (after exceptional and/or Extraordinary items)	464.35	200.86	1675.12	1660.39	410.07	338.49	1639.40	1798.02
4	Net Profit/ (Loss) for the period after tax (after exceptional and/or Extraordinary items)	414.34	146.11	1248.66	1225.89	364.69	249.33	1212.94	1329.12
5	Total comprehensive income for the period (Comprising Profit/ (loss) for the period (after tax) and other Comprehensive income (after tax))	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
6	Equity Share Capital	1221.66	1221.66	1221.66	1221.66	1221.66	1221.66	1221.66	1221.66
7	Reserves (excluding Revaluation Reserve as shown in the Balance Sheet of previous year)								
8	Earnings Per Share (of Rs.10/- each) (for continuing and discontinued operation)								
	Basic:	3.39	1.20	10.22	10.09	2.99	2.05	9.93	10.94
	Diluted:	3.39	1.20	10.22	10.09	2.99	2.05	9.93	10.94

Note:

- The above results after being reviewed by the Audit Committee have been taken on record by the Board at its Meeting held on 26th June 2021.
- This statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- The company operates only in one business segment, viz. Pharmaceuticals formulations, hence segment reporting is not applicable.
- The Earning Per Share has been calculated as per Indian Accounting Standard (Ind AS) 33 - "Earning per Share".
- During the quarter under review, major of the manufacturing facilities was shut down for 5-6 weeks for upgradation of plant as per regulatory market requirement for future growth.
- Audit report has been carried out by the Statutory Auditors for the above period.
- The figures are regrouped in previous year also, wherever considered necessary, to make them comparable.

For Medicamen Biotech Limited

Sd/-

Rahul Bishnoi

Chairman

Place: New Delhi

Date : 26.06.2021

दीपक अरनेजा (प्रबन्ध निदेशक तथा सीईओ) के द्वारा जारी किया गया है।
 हिट प्रवर्तन नियम 2002
 उपयोग करते हुए निम्नांकित
 ऋणी/ गारन्टर को विवेक
 है कि वे निम्नलिखित सं
 भी लेन-देन बैंक ऑफ
 बकाया राशि रु. 15,81
 और उन्नीस पैसे मात्र
 के अधीन होगा।
 अधिनियम की धारा 13
 लिए उपलब्ध समय के स
 अच

श्री मदन झा के नाम
 रोहिणी, नई दिल्ली -
 उप-जिला एसआर VI
 चौहददी:

उत्तर में : म
 पूर्व में : अन्य

स्थान: दिल्ली
 दिनांक: 22.06.2020



सम्यक नं. 01
 31 मार्च, 2021 को

विवरण

प्रचालनों से कुल आय

शुद्ध लाभ/(हानि) अवधि के
 (कर से पूर्व/कर एवं विशिष्ट
 असाधारण मदों एवं अन्य व्य
 आय के बाद)

इक्विटी शेयर पूंजी

आरक्षित (पुनर्मुल्यांकन आर
 छोड़कर)

आय प्रति शेयर (रु. 10/- प्र
 (जारी तथा अवरुद्ध प्रचालनों

- मूल:
- तरल:

टिप्पणी:

- कम्पनी के अंकेक्षित
 नियमावली, 2016 द
 अंतर्गत अधिसूचित
- उपरोक्त अंकेक्षित वि
 को आयोजित उनकी
- उपरोक्त सेबी (सू
 CIR/CFD/FAC
 अंतर्गत स्टॉक एक्सचें
 है। समाप्त तिमाही /
 अर्थात् www.bse.in

स्थान: नई दिल्ली
 तिथि: 25.06.2021